Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

Clinical Trial ID NCT00137423

Rank	Title	Journal	Year	PubWeight™‹?›
1	Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.	Br J Cancer	2014	2.26
2	Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.	Eur Urol	2014	2.23
3	Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.	J Clin Oncol	2009	2.09
4	Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.	Clin Cancer Res	2015	1.53
5	Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.	Br J Cancer	2013	1.24
6	A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.	Curr Cancer Drug Targets	2012	1.12
7	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.	Eur Urol	2015	0.92
8	Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma.	Eur Urol	2015	0.84
9	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.	J Clin Oncol	2016	0.76
10	Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.	Eur Urol	2016	0.75